Dakota Wealth Management Sells 3,920 Shares of Zoetis Inc. $ZTS

Key Points

• Dakota Wealth Management has reduced its stake in Zoetis Inc. by 6.0%, selling 3,920 shares, leading to a total holding of 61,621 shares worth approximately $9.61 million.
• Zoetis recently surpassed analysts' earnings expectations, reporting $1.76 EPS for the quarter and a revenue of $2.46 billion, a 4.2% increase from the previous year.
• Wall Street analysts have mixed ratings on Zoetis, with a consensus average rating of "Moderate Buy" and an average target price of $200.88.

Dakota Wealth Management cut its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 6.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 61,621 shares of the company's stock after selling 3,920 shares during the quarter. Dakota Wealth Management's holdings in Zoetis were worth $9,610,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ZTS. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH purchased a new position in Zoetis in the 2nd quarter worth $2,074,000. Perigon Wealth Management LLC increased its position in shares of Zoetis by 0.5% in the second quarter. Perigon Wealth Management LLC now owns 24,201 shares of the company's stock valued at $3,774,000 after acquiring an additional 114 shares during the period. Castleview Partners LLC grew its position in shares of Zoetis by 2.7% in the 2nd quarter. Castleview Partners LLC now owns 3,865 shares of the company's stock worth $603,000 after buying an additional 100 shares during the last quarter. Sylvest Advisors LLC bought a new stake in shares of Zoetis in the 2nd quarter worth approximately $813,000. Finally, Retirement Guys Formula LLC grew its position in shares of Zoetis by 10.9% in the 2nd quarter. Retirement Guys Formula LLC now owns 6,180 shares of the company's stock worth $964,000 after buying an additional 606 shares during the last quarter. Institutional investors own 92.80% of the company's stock.

Zoetis Price Performance

NYSE ZTS opened at $141.65 on Thursday. The company has a market capitalization of $62.78 billion, a PE ratio of 24.38, a price-to-earnings-growth ratio of 2.29 and a beta of 0.89. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The business's fifty day moving average is $150.63 and its 200 day moving average is $156.07. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $197.51.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company had revenue of $2.46 billion for the quarter, compared to analysts' expectations of $2.41 billion. During the same quarter last year, the business earned $1.56 EPS. The firm's revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ZTS has been the subject of several research reports. Argus reissued a "buy" rating and issued a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Piper Sandler upped their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Finally, Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and reduced their price target for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, Zoetis presently has an average rating of "Moderate Buy" and a consensus target price of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.